Toutes les études
RecrutementPHASE2INTERVENTIONNEL

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

This research study is looking into a new medication called NBI-1117570 for adults with schizophrenia. The main goal is to find out if this new medicine can help improve the challenging thoughts and feelings (sometimes called behavioural and psychological symptoms) that people experience during an acute flare-up of their condition. Participants in this study will be adults aged 18 to 55 who are currently in hospital due to their schizophrenia symptoms. Some participants will receive the new medicine, while others will get a placebo (a dummy pill with no active ingredients) to compare the effects. This will help doctors understand if NBI-1117570 is an effective and safe treatment option.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2
Sponsor
Neurocrine Biosciences
Objectif d'inscription
120
Démarrer
16 fév 2026
Achèvement estimé
01 Aug 2027

De quoi parle cette étude ?

Schizophrenia is a complex mental health condition that can affect how a person thinks, feels, and behaves. Sometimes, people with schizophrenia experience a sudden worsening of their symptoms, often called an 'acute flare-up'. When this happens, they might need to stay in hospital for support and treatment.

This study is testing a new medicine called NBI-1117570. The researchers want to see if this new medicine can help people who are experiencing an acute flare-up of their schizophrenia symptoms. They will compare it to a 'placebo', which is a pill that looks exactly like the study medicine but doesn't contain any active drug. This comparison helps doctors understand if any improvements seen are truly due to the new medicine or if they might happen naturally or due to other care.

The main aim of this study is to check if NBI-1117570 can effectively reduce the challenging thoughts, feelings, and behaviours associated with schizophrenia during these flare-ups. Learning more about new treatments like this is important because it could lead to better ways to help people manage their condition and improve their quality of life.

Points clés

  • This study is for adults (18-55) in hospital with a schizophrenia flare-up.
  • It tests a new medicine (NBI-1117570) against a dummy pill (placebo).
  • The goal is to see if the new medicine improves schizophrenia symptoms.
  • Your safety and well-being are the top priority throughout the study.
  • La participation est volontaire, et vous pouvez vous retirer à tout moment.

Qui peut être éligible ?

To join this study, you need to be an adult between 18 and 55 years old and have been diagnosed with schizophrenia for at least one year. You must also be currently in hospital because of a recent flare-up of your schizophrenia symptoms, which started less than two months ago. It's also important that you've had a positive response to at least one antipsychotic medicine for a previous flare-up (though not clozapine).

There are also some reasons why you might not be able to join. For example, if there's a serious risk to your safety or the safety of others, or if you have a history of seizures or fits. Certain heart conditions, being pregnant or breastfeeding, or taking medications that might interfere with the study medicine, would also mean you couldn't take part. The study team will review all your medical information carefully to make sure it's safe for you to participate.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 18 and 55 years old?
  2. Have you been diagnosed with schizophrenia for at least one year?
  3. Are you currently in hospital due to a schizophrenia flare-up that started recently?
  4. Have you responded well to another antipsychotic medicine (not clozapine) for a past flare-up?
  5. Do you have a history of seizures or serious heart conditions?
  6. Êtes-vous enceinte ou allaitez-vous ?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you'll be part of a group helping to test this new medicine. You would receive either the new medicine, NBI-1117570, or a placebo (a dummy pill). You won't know which one you are getting, and neither will your doctors, to ensure the results are fair. You'll have regular visits where doctors will check your health, ask about your symptoms, and do medical tests. This is to make sure the medicine is safe and to see if it's helping. The study will continue as long as you need to be in hospital for this episode, and potentially beyond, though the exact duration isn't specified here.

Risques et avantages potentiels

Taking part in a study like this could potentially offer benefits, such as receiving a new medicine that might help your symptoms. However, there's no guarantee the new medicine will work for you, and you might receive a placebo. There are also potential risks, as all medicines can have side effects. These will be fully explained to you before you agree to take part. Your safety and well-being will be checked very carefully throughout the study. Remember, joining is completely voluntary, and you are free to change your mind and leave the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (6)

  • Neurocrine Clinical Site
    Code postal vérifié
    Kazanlak, Bulgaria· Recrutement
  • Neurocrine Clinical Site
    Code postal vérifié
    Pazardzhik, Bulgaria· Recrutement
  • Neurocrine Clinical Site
    Code postal vérifié
    Targovishte, Bulgaria· Recrutement
  • Neurocrine Clinical Site
    Code postal vérifié
    Târgu Mureş, Romania· Recrutement
  • Neurocrine Clinical Site
    Code postal vérifié
    Londres, Royaume-Uni· Recrutement
  • Neurocrine Clinical Site
    Code postal vérifié
    Oxford, Royaume-Uni· Recrutement

Questions fréquentes

Qu'est-ce qu'un placebo ?

A placebo is a 'dummy pill' that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the effects of the real medicine.

Will I know if I'm getting the new medicine or the placebo?

No, neither you nor your doctors will know if you are receiving the new medicine or the placebo. This is to keep the study fair and accurate.

What happens if the new medicine doesn't work for me?

Your health will be closely monitored. If the medicine isn't helping or if your symptoms worsen, the study doctors will adjust your care as needed, just like in standard treatment.

Puis-je quitter l'étude si je change d'avis ?

Yes, you can leave the study at any time, for any reason, without it affecting your medical care.

Will my regular doctors still be involved in my care?

Yes, your usual medical team will continue to be involved and informed about your care, working alongside the study team.

Comment en savoir plus

Neurocrine Medical Information Call Center

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Evaluation of NBI-1117570 in Inpatient Adults With Schizophr… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.